Applicability of glucocorticoid toxicity index in pemphigus: Comparison between two groups of rituximab-treated and rituximab-naïve patients.
COVID-19
autoimmune blistering diseases
glucocorticoid toxicity index (GTI)
glucocorticoids
pemphigus
rituximab
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
19
07
2022
accepted:
02
10
2022
pubmed:
7
10
2022
medline:
21
12
2022
entrez:
6
10
2022
Statut:
ppublish
Résumé
Rituximab (RTX) combined with short-term glucocorticoids (GC) is an effective therapeutic option for pemphigus. The newly developed Glucocorticoid Toxicity Index (GTI) tool provides the possibility to measure GC toxicities over time. To compare 1-year GTI between two groups of RTX-treated and RTX-naïve patients with pemphigus. The responsiveness of the GTI was also investigated. A prospective cohort of 129 adults with newly diagnosed pemphigus was conducted. GC-related toxicities were assessed at 3-month intervals according to Composite and Specific lists of the GTI. Of the patients, 76.7% (n = 99) received RTX. Throughout the time intervals, RTX-treated patients had lower GTI compared to RTX-naïve ones (p = 0.036). The mean GTI at 1-year was 34.3 in the RTX-treated group and 50.8 in the RTX-naïve group (p = 0.04). The most commonly observed GC-related toxicity was neuropsychiatric manifestations for 34% (224 events). The relapse rate of RTX-treated patients (1%) was significantly lower than RTX-naïve patients (10%) (p = 0.037). The GTI showed no correlation with cumulative GC consumption in both groups (p > 0.05, both). Patients treated with GC alone had remarkably higher GTI than patients treated with GC plus RTX. The GTI is an applicable tool to quantitatively capture GC toxicities at the patient level in pemphigus.
Substances chimiques
Rituximab
4F4X42SYQ6
Glucocorticoids
0
Immunologic Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15902Subventions
Organisme : Tehran University of Medical Sciences and Health Services
ID : 99-1-101-46059
Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Bilgic A, Murrell DF. What is novel in the clinical management of pemphigus. Expert Review of Clinical Pharmacology. 2019;12(10):973-980.
Toosi R, Mahmoudi H, Balighi K, et al. Efficacy and safety of biosimilar rituximab in patients with pemphigus vulgaris: a prospective observational study. J Dermatolog Treat. 2021;32(1):33-40.
Schmidt E, Kasperkiewicz M, Joly P. Pemphigus. Lancet. 2019;394(10201):882-894.
Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. Ann Rheum Dis. 2009;68(7):1119-1124.
Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703.
Yao TC, Huang YW, Chang SM, Tsai SY, Wu AC, Tsai HJ. Association between Oral corticosteroid bursts and severe adverse events: a Nationwide population-based cohort study. Ann Intern Med. 2020;173(5):325-330.
Alten R, Mischkewitz M. New concepts to reduce glucocorticoid toxicity. Joint Bone Spine. 2019;86(6):715-723.
Balighi K, Daneshpazhooh M, Mahmoudi H, et al. Comparing early and late treatments with rituximab in pemphigus vulgaris: which one is better? Arch Dermatol Res. 2019;311(1):63-69.
Didona D, Maglie R, Eming R, Hertl M. Pemphigus: current and future therapeutic strategies. Front Immunol. 2019;10:1418.
Tavakolpour S, Mahmoudi H, Balighi K, Abedini R, Daneshpazhooh M. Sixteen-year history of rituximab therapy for 1085 pemphigus vulgaris patients: a systematic review. Int Immunopharmacol. 2018;54:131-138.
Gupta J, Raval RC, Shah AN, et al. Low-dose rituximab as an adjuvant therapy in pemphigus. Indian J Dermatol Venereol Leprol. 2017;83(3):317-325.
Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the European academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020;34(9):1900-1913.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. Lancet. 2017;389(10083):2031-2040.
Kridin K, Ahn C, Huang WC, Ansari A, Sami N. Treatment update of autoimmune blistering diseases. Dermatol Clin. 2019;37(2):215-228.
Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations of an international panel of experts. J Am Acad Dermatol. 2020;82(3):575-585.e1.
Chen DM, Odueyungbo A, Csinady E, et al. Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. Br J Dermatol. 2020;182(5):1111-1119.
Miloslavsky EM, Naden RP, Bijlsma JW, et al. Development of a glucocorticoid toxicity index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543-546.
Daneshpazhooh M, Balighi K, Mahmoudi H, et al. Iranian guideline for rituximab therapy in pemphigus patients. Dermatol Ther. 2019;32(5):e13016.
Husted JA, Cook RJ, Farewell VT, Gladman DD. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol. 2000 May;53(5):459-468.
Risser J, Lewis K, Weinstock MA. Mortality of bullous skin disorders from 1979 through 2002 in the United States. Arch Dermatol. 2009;145(9):1005-1008.
Cholera M, Chainani-Wu N. Management of Pemphigus Vulgaris. Adv Ther. 2016;33(6):910-958.
Kianfar N, Dasdar S, Mahmoudi H, Daneshpazhooh M. Burden of pemphigus vulgaris with a particular focus on women: a review. Int J Women's Dermatol. 2022;8(3):e056.
Keeley JM, Bevans SL, Jaleel T, Sami N. Rituximab and low dose oral immune modulating treatment to maintain a sustained response in severe pemphigus patients. J Dermatolog Treat. 2019;30(4):340-345.
Kianfar N, Dasdar S, Mahmoudi H, Tavakolpour S, Balighi K, Daneshpazhooh M. Rituximab in childhood and juvenile autoimmune bullous diseases as first-line and second-line treatment: a case series of 13 patients. J Dermatolog Treat. 2020;7:1-6.
Dehghanimahmoudabadi A, Kianfar N, Akhdar M, et al. Pregnancy outcomes in women with pemphigus exposed to rituximab before or during pregnancy. Int J Women's Dermatol. 2022;8(3):e038.
Vinay K, Dogra S. Rituximab in pemphigus: road covered and challenges ahead. Indian Dermatol Online J. 2018;9(6):367-372.
Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-866.
Mahmoudi H, Farid AS, Nili A, et al. Characteristics and outcomes of COVID-19 in patients with autoimmune bullous diseases: a retrospective cohort study. J Am Acad Dermatol. 2021;84(4):1098-1100.
Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159(2):481-491.e3.
McDowell PJ, Stone JH, Zhang Y, et al. Quantification of glucocorticoid-associated morbidity in severe asthma using the glucocorticoid toxicity index. J Allergy Clin Immunol Pract. 2021;9(1):365-372.e5.
Liang Y, Zeng FAP, Sheriff T, et al. Evaluation of the toxicity of glucocorticoids in patients with autoimmune blistering disease using the glucocorticoid toxicity index: a cohort study. JAAD Int. 2022;6:68-76.